{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T12:49:05Z","timestamp":1781700545230,"version":"3.54.5"},"reference-count":36,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.urolonc.2024.09.026","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T05:12:26Z","timestamp":1728018746000},"page":"450.e1-450.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Intra-arterial chemotherapy combined with BCG immunotherapy is more effective than intra-arterial chemotherapy plus intravesical chemotherapy or standard BCG immunotherapy in preventing the recurrence and progression of high-risk non\u2013muscle-invasive bladder cancer"],"prefix":"10.1016","volume":"42","author":[{"given":"Shuhang","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wumier","family":"Wusimanjiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enyou","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingwu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junxing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.urolonc.2024.09.026_bib0001","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"13","key":"10.1016\/j.urolonc.2024.09.026_bib0002","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.3390\/cancers14133181","article-title":"Advances in diagnosis and therapy for bladder cancer","volume":"14","author":"Hu","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.urolonc.2024.09.026_bib0003","doi-asserted-by":"crossref","first-page":"5","DOI":"10.21037\/tau.2018.09.11","article-title":"Epidemiology, aetiology and screening of bladder cancer","volume":"8","author":"Cumberbatch","year":"2019","journal-title":"Transl Androl Urol"},{"issue":"10083","key":"10.1016\/j.urolonc.2024.09.026_bib0004","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(17)30874-7","article-title":"Evolution and patterns of global health financing 1995-2014: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries","volume":"389","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.urolonc.2024.09.026_bib0005","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.hoc.2021.02.001","article-title":"The epidemiology of bladder cancer","volume":"35","author":"Mossanen","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"issue":"3","key":"10.1016\/j.urolonc.2024.09.026_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.09.026_bib0007","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"issue":"4 Pt 1","key":"10.1016\/j.urolonc.2024.09.026_bib0008","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1097\/01.ju.0000140456.42509.b6","article-title":"Effective bladder sparing therapy with intra-arterial cisplatin and radiotherapy for localized bladder cancer","volume":"172","author":"Eapen","year":"2004","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2024.09.026_bib0009","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1046\/j.1442-2042.2000.00137.x","article-title":"A bladder preservation regimen using intra-arterial chemotherapy and radiotherapy for invasive bladder cancer: a prospective study","volume":"7","author":"Miyanaga","year":"2000","journal-title":"Int J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2024.09.026_bib0010","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ejso.2014.07.043","article-title":"Efficacy and safety of systemic chemotherapy and intra-arterial chemotherapy with\/without radiotherapy for bladder preservation or as neo-adjuvant therapy in patients with muscle-invasive bladder cancer: a single-center study of 163 patients","volume":"41","author":"Miyata","year":"2015","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2024.09.026_bib0011","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s00270-013-0594-2","article-title":"Comparing intra-arterial chemotherapy combined with intravesical chemotherapy versus intravesical chemotherapy alone: a randomized prospective pilot study for T1G3 bladder transitional cell carcinoma after bladder-preserving surgery","volume":"36","author":"Chen","year":"2013","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"2","key":"10.1016\/j.urolonc.2024.09.026_bib0012","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00432-018-2811-5","article-title":"Evaluation of the effects of intra-arterial chemotherapy combined with intravesical chemotherapy against intravesical chemotherapy alone after transurethral resection of bladder tumor in T1-staged Grade 3 bladder cancer","volume":"145","author":"Huang","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2024.09.026_bib0013","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1007\/s00432-020-03453-x","article-title":"Intra-arterial chemotherapy combined with intravesical chemotherapy compared with intravesical BCG immunotherapy retrospectively in high-risk non-muscle-invasive bladder cancer after transurethral resection of the bladder tumor","volume":"147","author":"Huang","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"issue":"21","key":"10.1016\/j.urolonc.2024.09.026_bib0014","doi-asserted-by":"crossref","first-page":"7800","DOI":"10.1002\/cam4.3513","article-title":"Efficacy of intravesical therapies on the prevention of recurrence and progression of non-muscle-invasive bladder cancer: a systematic review and network meta-analysis","volume":"9","author":"Lu","year":"2020","journal-title":"Cancer Med"},{"issue":"5","key":"10.1016\/j.urolonc.2024.09.026_bib0015","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.juro.2016.12.090","article-title":"Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis","volume":"197","author":"Chou","year":"2017","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2024.09.026_bib0016","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.juro.2010.06.147","article-title":"Bacillus Calmette-Gu\u00e9rin with or without interferon \u03b1-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer","volume":"184","author":"Nepple","year":"2010","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2024.09.026_bib0017","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma In situ) - 2019 Update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2024.09.026_bib0018","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/iju.12749","article-title":"Exploration of risk factors predicting outcomes for primary T1 high-grade bladder cancer and validation of the Spanish urological club for oncological treatment scoring model: long-term follow-up experience at a single institute","volume":"22","author":"Miyake","year":"2015","journal-title":"Int J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.09.026_bib0019","doi-asserted-by":"crossref","first-page":"15268","DOI":"10.1038\/s41598-019-51889-0","article-title":"BCG instillation versus radical cystectomy for high-risk NMIBC with squamous\/glandular histologic variants","volume":"9","author":"Suh","year":"2019","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.urolonc.2024.09.026_bib0020","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s00432-019-02900-8","article-title":"Intra-arterial chemotherapy combined with intravesical chemotherapy is effective in preventing recurrence in non-muscle invasive bladder cancer","volume":"145","author":"Lian","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.09.026_bib0021","unstructured":"RxList. PHARMORUBICIN (EPIRUBICIN) DRUG. Available from: https:\/\/www.rxlist.com\/pharmorubicin-drug.htm. Accessed 30 December, 2020."},{"key":"10.1016\/j.urolonc.2024.09.026_bib0022","unstructured":"RxList. CISPLATIN (CISPLATIN INJECTION) DRUG. Available from:https:\/\/www.rxlist.com\/cisplatin-drug.htm. Accessed 30 December, 2020."},{"issue":"253","key":"10.1016\/j.urolonc.2024.09.026_bib0023","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/01621459.1951.10500769","article-title":"The Kolmogorov-Smirnov test for goodness of fit","volume":"46","author":"Massey","year":"1951","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"10.1016\/j.urolonc.2024.09.026_bib0024","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J Royal Stat Soc: series B (Methodological)"},{"key":"10.1016\/j.urolonc.2024.09.026_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2288-13-152","article-title":"Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome","volume":"13","author":"Royston","year":"2013","journal-title":"BMC medical Research Methodology"},{"issue":"10","key":"10.1016\/j.urolonc.2024.09.026_bib0026","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41585-018-0055-4","article-title":"Mechanisms of BCG immunotherapy and its outlook for bladder cancer","volume":"15","author":"Pettenati","year":"2018","journal-title":"Nat Rev Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2024.09.026_bib0027","doi-asserted-by":"crossref","first-page":"P10","DOI":"10.1002\/aorn.12133","article-title":"Radical cystectomy","volume":"107","author":"Hauk","year":"2018","journal-title":"Aorn J"},{"issue":"9","key":"10.1016\/j.urolonc.2024.09.026_bib0028","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/13543784.2019.1655730","article-title":"Current advances in BCG-unresponsive non-muscle invasive bladder cancer","volume":"28","author":"Tse","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"10.1016\/j.urolonc.2024.09.026_bib0029","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00345-021-03908-x","article-title":"Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage","volume":"40","author":"Balasubramanian","year":"2022","journal-title":"World J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2024.09.026_bib0030","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00345-018-2437-x","article-title":"Efficacy of intra-arterial chemotherapy combined with intravesical chemotherapy in T1G3 bladder cancer when compared with intravesical chemotherapy alone after bladder-sparing surgery: a retrospective study","volume":"37","author":"Huang","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2024.09.026_bib0031","article-title":"The efficacy of intra-arterial plus intravesical chemotherapy versus intravesical chemotherapy alone after bladder-sparing surgery in high-risk bladder cancer: a systematic review and meta-analysis of comparative study","volume":"11","author":"Zhou","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2024.09.026_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.707271","article-title":"Efficacy of intra-arterial plus intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer: a pooled analysis","volume":"12","author":"Cheng","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.urolonc.2024.09.026_bib0033","doi-asserted-by":"crossref","first-page":"e12248","DOI":"10.7717\/peerj.12248","article-title":"Application of intra-arterial chemotherapy in high-risk non-muscle invasive bladder cancer: a systematic review and meta-analysis","volume":"9","author":"You","year":"2021","journal-title":"PeerJ"},{"issue":"6","key":"10.1016\/j.urolonc.2024.09.026_bib0034","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","article-title":"Results of a randomized controlled trial comparing intravesical chemo hyperthermia with mitomycin c versus bacillus calmette-gu\u00e9rin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer","volume":"69","author":"Arends","year":"2016","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2024.09.026_bib0035","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1442-2042.1997.tb00292.x","article-title":"Internal iliac arterial infusion chemotherapy for rabbit invasive bladder cancer","volume":"4","author":"Hoshi","year":"1997","journal-title":"Int J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.09.026_bib0036","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924006665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924006665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T08:34:05Z","timestamp":1731746045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924006665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1078143924006665"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.09.026","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intra-arterial chemotherapy combined with BCG immunotherapy is more effective than intra-arterial chemotherapy plus intravesical chemotherapy or standard BCG immunotherapy in preventing the recurrence and progression of high-risk non\u2013muscle-invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.09.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}